June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Amol Akhade: Matterhorn Trial: ASCO 2025 Spotlight 
May 30, 2025, 22:44

Amol Akhade: Matterhorn Trial: ASCO 2025 Spotlight 

Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on X:

Matterhorn Trial – ASCO 2025 Spotlight 
Can perioperative immunotherapy change outcomes in resectable gastric/GEJ cancer?
At GI25, MATTERHORN (Durvalumab + FLOT) showed:
pCR: 19% vs 7%
T0: 23% vs 11%
N0: 52% vs 36%
As Per press release: EFS is statistically significant and clinically meaningful.
But KN585 – PCR BENIFIT but no EFS gain
Why MATTERHORN may succeed where KEYNOTE-585 fell short:
100% got triplet chemo (vs 20% in KN585)
60% completed peri-op FLOT (vs 48 % )
Now your turn- put your brain and give me your best guess for the EFS outcome?
HR and Gain in median EFS
See the POLL and Vote
So for matterhorn , we are not so sure about magnitude of benifit? 
34 % around feel that magnitude of EFS gain will be 8 to 10 months over FlOT alone .”